Lymphocyte roles in metabolic dysfunction: Of men and mice

Trends in Endocrinology and Metabolism

Volumn 26, Issue 2, 2015, Pages 91-100

  Ip, Blanche C ^a   Hogan, Andrew E ^b   Nikolajczyk, Barbara S ^a,c  

^a BOSTON UNIVERSITY   (United States)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Insulin resistance; Lymphocyte subsets; Obesity; Type 2 diabetes

Indexed keywords

ANTIINFLAMMATORY AGENT; CD40 LIGAND; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; BODY MASS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; INNATE IMMUNITY; INNATE LYMPHOID CELL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INVARIANT NATURAL KILLER T CELL; LYMPHOCYTE FUNCTION; LYMPHOID CELL; MACROPHAGE; MEMORY T LYMPHOCYTE; METABOLIC DISORDER; METABOLIC STRESS; MOUSE; MOUSE MODEL; NATURAL KILLER T CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SYSTEMIC CIRCULATION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; ADIPOCYTE; ANIMAL; COMPLICATION; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE; MALE; METABOLISM; PHYSIOLOGY;

ADIPOCYTES; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; LYMPHOCYTES; MALE; METABOLIC DISEASES; MICE; OBESITY;

EID: 84923094589     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.12.001     Document Type: Review

References (124)

1. Samocha-Bonet D., et al. Metabolically healthy and unhealthy obese: the 2013 Stock Conference report. Obes. Rev. 2014, 15:697-708.
2. Denis G.V., Obin M.S. 'Metabolically healthy obesity': origins and implications. Mol. Aspects Med. 2013, 34:59-70.
3. Lee C.T., et al. White blood cell subtypes, insulin resistance and beta-cell dysfunction in high-risk individuals: the PROMISE cohort. Clin. Endocrinol. (Oxf.) 2014, 81:536-541.
4. Achilike I., et al. Predicting the development of the metabolically healthy obese phenotype. Int. J. Obes. (Lond.) 2014, Published online July 2, 2014. 10.1038/ijo.2014.113.
5. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
6. Wernstedt Asterholm I., et al. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab. 2014, 20:103-118.
7. Oh D.Y., et al. Increased macrophage migration into adipose tissue in obese mice. Diabetes 2012, 61:346-354.
8. Dalmas E., et al. T cell-derived IL-22 amplifies IL-1beta-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes. Diabetes 2014, 63:1966-1977.
9. Gadd V.L., et al. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology 2014, 59:1393-1405.
10. Nakamura K., et al. Adipokines: a link between obesity and cardiovascular disease. J. Cardiol. 2014, 63:250-259.
11. Procaccini C., et al. Role of adipokines signaling in the modulation of T cells function. Front. Immunol. 2013, 4:332.
12. Ohashi K., et al. Role of anti-inflammatory adipokines in obesity-related diseases. Trends Endocrinol. Metab. 2014, 25:348-355.
13. Nikolajczyk B.S., et al. The outliers become a stampede as immunometabolism reaches a tipping point. Immunol. Rev. 2012, 249:253-275.
14. van Beek L., et al. Increased systemic and adipose tissue inflammation differentiates obese women with T2DM from obese women with normal glucose tolerance. Metabolism 2014, 63:492-501.
15. Fabbrini E., et al. Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals. Gastroenterology 2013, 145:366-374. e363.
16. Jagannathan-Bogdan M., et al. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J. Immunol. 2011, 186:1162-1172.
17. Wagner N.M., et al. Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. Obesity 2013, 21:461-468.
18. Sun K., et al. Adipose tissue remodeling and obesity. J. Clin. Invest. 2011, 121:2094-2101.
19. Zaragosi L.E., et al. Activin a plays a critical role in proliferation and differentiation of human adipose progenitors. Diabetes 2010, 59:2513-2521.
20. Wentworth J.M., et al. Pro-inflammatory CD11c+ CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes 2010, 59:1648-1656.
21. Kratz M., et al. Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. Cell Metab. 2014, 20:614-625.
22. Winer S., et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med. 2009, 15:921-929.
23. Duffaut C., et al. Unexpected trafficking of immune cells within the adipose tissue during the onset of obesity. Biochem. Biophys. Res. Commun. 2009, 384:482-485.
24. Nishimura S., et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 2009, 15:914-920.
25. Rausch M., et al. Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int. J. Obes. (Lond.) 2007, 32:451-463.
26. Elgazar-Carmon V., et al. Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. J. Lipid Res. 2008, 49:1894-1903.
27. Nguyen M.A., et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J. Biol. Chem. 2007, 282:35279-35292.
28. Wu H., et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 2007, 115:1029-1038.
29. Yang H., et al. Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance. J. Immunol. 2010, 185:1836-1845.
30. DeFuria J., et al. B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:5133-5138.
31. Chatzigeorgiou A., et al. Lymphocytes in obesity-related adipose tissue inflammation. Diabetologia 2012, 55:2583-2592.
32. Rocha V.Z., et al. CXCR3 controls T-cell accumulation in fat inflammation. Arterioscler. Thromb. Vasc. Biol. 2014, 34:1374-1381.
33. Yang H., et al. Obesity accelerates thymic aging. Blood 2009, 114:3803-3812.
34. Deng T., et al. Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammation. Cell Metab. 2013, 17:411-422.
35. Winer D.A., et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat. Med. 2011, 17:610-617.
36. Mazzone T., et al. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008, 371:1800-1809.
37. van Panhuys N., et al. T-cell-receptor-dependent signal intensity dominantly controls CD4(+) T cell polarization in vivo. Immunity 2014, 41:63-74.
38. Kägi D., et al. Homeostatic regulation of CD8+ T cells by perforin. Eur. J. Immunol. 1999, 29:3262-3272.
39. Pacifico L., et al. Increased T-helper interferon-γ-secreting cells in obese children. Eur. J. Endocrinol. 2006, 154:691-697.
40. Zeng C., et al. The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. J. Mol. Med. 2012, 90:175-186.
41. Mayer A., et al. Antigen presenting cell-derived IL-6 restricts Th2-cell differentiation. Eur. J. Immunol. 2014, 44:3252-3262.
42. Muranski P., Restifo N.P. Essentials of Th17 cell commitment and plasticity. Blood 2013, 121:2402-2414.
43. Zhao R., et al. Elevated peripheral frequencies of Th22 cells: a novel potent participant in obesity and type 2 diabetes. PLoS ONE 2014, 9:e85770.
44. Sumarac-Dumanovic M., et al. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int. J. Obes. (Lond.) 2009, 33:151-156.
45. Ghoreschi K., et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 2010, 467:967-971.
46. Chuang H.C., et al. HGK/MAP4K4 deficiency induces TRAF2 stabilization and Th17 differentiation leading to insulin resistance. Nat. Commun. 2014, 5:4602.
47. Yu Y., et al. Cutting edge: leptin-induced RORγt expression in CD4+ T cells promotes Th17 responses in systemic lupus erythematosus. J. Immunol. 2013, 190:3054-3058.
48. Alkazemi D., et al. Oxysterol as a marker of atherogenic dyslipidemia in adolescence. J. Clin. Endocrinol. Metab. 2008, 93:4282-4289.
49. Soroosh P., et al. Oxysterols are agonist ligands of RORγt and drive Th17 cell differentiation. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:12163-12168.
50. Winer S., et al. Obesity predisposes to Th17 bias. Eur. J. Immunol. 2009, 39:2629-2635.
51. Zúñiga L.A., et al. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J. Immunol. 2010, 185:6947-6959.
52. Harley I.T., et al. IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology 2014, 59:1830-1839.
53. Korn T., et al. IL-17 and Th17 Cells. Annu. Rev. Immunol. 2009, 27:485-517.
54. Shin J.H., et al. Interleukin-17A inhibits adipocyte differentiation in human mesenchymal stem cells and regulates pro-inflammatory responses in adipocytes. Biochem. Pharmacol. 2009, 77:1835-1844.
55. Li L., et al. IL-17 produced by neutrophils regulates IFN-γ-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J. Clin. Invest. 2010, 120:331-342.
56. Spits H., et al. Innate lymphoid cells: a proposal for uniform nomenclature. Nat. Rev. Immunol. 2013, 13:145-149.
57. Ramesh R., et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J. Exp. Med. 2014, 211:89-104.
58. Lee Y., et al. Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 2012, 13:991-999.
59. Duhen T., et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat. Immunol. 2009, 10:857-863.
60. Trifari S., et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells. Nat. Immunol. 2009, 10:864-871.
61. Sabat R., et al. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat. Rev. Drug Discov. 2014, 13:21-38.
62. Aggarwal S., et al. Acinar cells of the pancreas are a target of interleukin-22. J. Interferon Cytokine Res. 2001, 21:1047-1053.
63. Shioya M., et al. Interleukin 22 receptor 1 expression in pancreas islets. Pancreas 2008, 36:197-199.
64. Xue J., et al. Aryl hydrocarbon receptor regulates pancreatic IL-22 production and protects mice from acute pancreatitis. Gastroenterology 2012, 143:1670-1680.
65. Hill T., et al. The involvement of interleukin-22 in the expression of pancreatic beta cell regenerative Reg genes. Cell Regen. 2013, 2:2.
66. Wang X., et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature 2014, 514:237-241.
67. Feuerer M., et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 2009, 15:930-939.
68. Eller K., et al. Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy. Diabetes 2011, 60:2954-2962.
69. Ilan Y., et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:9765-9770.
70. Okeke E.B., et al. Regulatory T cells restrain CD4+ T cells from causing unregulated immune activation and hypersensitivity to lipopolysaccharide challenge. J. Immunol. 2014, 193:655-662.
71. Okoye I.S., et al. MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells. Immunity 2014, 41:89-103.
72. Kelada S., et al. miR-182 and miR-10a are key regulators of Treg specialisation and stability during Schistosome and Leishmania-associated inflammation. PLoS Pathog. 2013, 9:e1003451.
73. Han J.M., et al. Insulin inhibits IL-10-mediated regulatory T cell function: implications for obesity. J. Immunol. 2014, 192:623-629.
74. Cipolletta D., et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012, 486:549-553.
75. De Rosa V., et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007, 26:241-255.
76. Liu Y., et al. Cutting edge: fasting-induced hypoleptinemia expands functional regulatory T cells in systemic lupus erythematosus. J. Immunol. 2012, 188:2070-2073.
77. Moraes-Vieira P.M., et al. Leptin deficiency impairs maturation of dendritic cells and enhances induction of regulatory T and Th17 cells. Eur. J. Immunol. 2014, 44:794-806.
78. Valmori D., et al. Human RORγt+ TH17 cells preferentially differentiate from naive FOXP3+ Treg in the presence of lineage-specific polarizing factors. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:19402-19407.
79. Porcelli S., et al. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J. Exp. Med. 1993, 178:1-16.
80. Exley M., et al. Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells. J. Exp. Med. 1997, 186:109-120.
81. Kawano T., et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997, 278:1626-1629.
82. Matsuda J.L., et al. CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system. Curr. Opin. Immunol. 2008, 20:358-368.
83. Lynch L., et al. Invariant NKT cells and CD1d+ cells amass in human omentum and are depleted in patients with cancer and obesity. Eur. J. Immunol. 2009, 39:1893-1901.
84. Schipper H.S., et al. Natural killer T cells in adipose tissue prevent insulin resistance. J. Clin. Invest. 2012, 122:3343-3354.
85. Ji Y., et al. Activation of natural killer T cells promotes M2 Macrophage polarization in adipose tissue and improves systemic glucose tolerance via interleukin-4 (IL-4)/STAT6 protein signaling axis in obesity. J. Biol. Chem. 2012, 287:13561-13571.
86. Lynch L., et al. Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity 2012, 37:574-587.
87. Carolan E., et al. The impact of childhood obesity on inflammation, innate immune cell frequency and metabolic microRNA expression. J. Clin. Endocrinol. Metab. 2013, 99:E474-E478.
88. Sag D., et al. IL-10-producing NKT10 cells are a distinct regulatory invariant NKT cell subset. J. Clin. Invest. 2014, 124:3725-3740.
89. Wu L., et al. Activation of invariant natural killer T cells by lipid excess promotes tissue inflammation, insulin resistance, and hepatic steatosis in obese mice. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E1143-E1152.
90. Kotas M.E., et al. Impact of CD1d deficiency on metabolism. PLoS ONE 2011, 6:e25478.
91. Huh J.Y., et al. A novel function of adipocytes in lipid antigen presentation to iNKT cells. Mol. Cell. Biol. 2013, 33:328-339.
92. Hams E., et al. Cutting edge: IL-25 elicits innate lymphoid type 2 and type II NKT cells that regulate obesity in mice. J. Immunol. 2013, 191:5349-5353.
93. Winer D.A., et al. B Lymphocytes in obesity-related adipose tissue inflammation and insulin resistance. Cell. Mol. Life Sci. 2014, 71:1033-1043.
94. Jagannathan M., et al. Toll-like receptors regulate B cell cytokine production in patients with diabetes. Diabetologia 2010, 53:1461-1471.
95. Dabelea D., et al. Diabetes autoantibodies do not predict progression to diabetes in adults: the Diabetes Prevention Program. Diabet. Med. 2014, 31:1064-1068.
96. Marzullo P., et al. Lymphocytes and immunoglobulin patterns across the threshold of severe obesity. Endocrine 2014, 45:392-400.
97. Kim Y.H., et al. B cell activation factor (BAFF) is a novel adipokine that links obesity and inflammation. Exp. Mol. Med. 2009, 41:208-216.
98. Tada F., et al. B cell activating factor in obesity is regulated by oxidative stress in adipocytes. J. Clin. Biochem. Nutr. 2013, 52:120-127.
99. Yan H., et al. Priming of Toll-like receptor 4 pathway in mesenchymal stem cells increases expression of B cell activating factor. Biochem. Biophys. Res. Commun. 2014, 448:212-217.
100. Garcia-Hernandez M.H., et al. Expression and function of P2X(7) receptor and CD39/Entpd1 in patients with type 2 diabetes and their association with biochemical parameters. Cell. Immunol. 2011, 269:135-143.
101. Nussbaum J.C., et al. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature 2013, 502:245-248.
102. Molofsky A.B., et al. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J. Exp. Med. 2013, 210:535-549.
103. Kim H.Y., et al. Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat. Med. 2014, 20:54-61.
104. Vivier E., et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49.
105. Guo H., et al. High frequency of activated natural killer and natural killer T-cells in patients with new onset of type 2 diabetes mellitus. Exp. Biol. Med. (Maywood) 2012, 237:556-562.
106. Lynch L.A., et al. Are natural killer cells protecting the metabolically healthy obese patient?. Obesity 2009, 17:601-605.
107. Nieman D.C., et al. Influence of obesity on immune function. J. Am. Diet. Assoc. 1999, 99:294-299.
108. O'Rourke R.W., et al. Systemic NK cell ablation attenuates intra-abdominal adipose tissue macrophage infiltration in murine obesity. Obesity 2014, 22:2109-2114.
109. Morris D.L., et al. Adipose tissue macrophages function as antigen-presenting cells and regulate adipose tissue CD4+ T cells in mice. Diabetes 2013, 62:2762-2772.
110. Seijkens T., et al. CD40-CD40L: linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications. Diab. Vasc. Dis. Res. 2013, 10:115-122.
111. Missiou A., et al. CD40L induces inflammation and adipogenesis in adipose cells: a potential link between metabolic and cardiovascular disease. Thromb. Haemost. 2010, 103:788-796.
112. Poggi M., et al. The inflammatory receptor CD40 is expressed on human adipocytes: contribution to crosstalk between lymphocytes and adipocytes. Diabetologia 2009, 52:1152-1163.
113. Unek I.T., et al. The levels of soluble CD40 ligand and C-reactive protein in normal weight, overweight and obese people. Clin. Med. Res. 2010, 8:89-95.
114. Poggi M., et al. CD40L deficiency ameliorates adipose tissue inflammation and metabolic manifestations of obesity in mice. Arterioscler. Thromb. Vasc. Biol. 2011, 31:2251-2260.
115. Wolf D., et al. CD40L deficiency attenuates diet-induced adipose tissue inflammation by impairing immune cell accumulation and production of pathogenic IgG-antibodies. PLoS ONE 2012, 7:e33026.
116. Guo C.A., et al. CD40 deficiency in mice exacerbates obesity-induced adipose tissue inflammation, hepatic steatosis, and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2013, 304:E951-E963.
117. Yi Z., et al. CD40-mediated maintenance of immune homeostasis in the adipose tissue microenvironment. Diabetes 2014, 63:2751-2760.
118. Zirlik A., et al. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation 2007, 115:1571-1580.
119. Zhong J., et al. T-cell costimulation protects obesity-induced adipose inflammation and insulin resistance. Diabetes 2014, 63:1289-1302.
120. Chatzigeorgiou A., et al. Dual role of B7 costimulation in obesity-related nonalcoholic steatohepatitis and metabolic dysregulation. Hepatology 2014, 60:1196-1210.
121. Goldfine A.B., et al. Therapeutic approaches to target inflammation in type 2 diabetes. Clin. Chem. 2011, 57:162-167.
122. Esser N., et al. Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia 2013, 56:2487-2497.
123. O'Rourke R.W., et al. Alterations in T-cell subset frequency in peripheral blood in obesity. Obes. Surg. 2005, 15:1463-1468.
124. van der Weerd K., et al. Morbidly obese human subjects have increased peripheral blood CD4+ T cells with skewing toward a Treg- and Th2-dominated phenotype. Diabetes 2012, 61:401-408.